FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.
What happened
FDA reviewed Xcel Research's website in October 2024 and found offers to sell peptide products including Retatrutide, Cagrilintide/Semaglutide, Mazdutide, Semaglutide, Survodutide, and Sermorelin. The site made claims that these products can manage weight, blood sugar, cardiovascular health, and other disease-related conditions, despite 'FOR RESEARCH USE ONLY' statements. FDA said the products are unapproved new drugs and not generally recognized as safe and effective for those uses.
What FDA found
Website claims show the products are intended for human use as drugs, despite 'FOR RESEARCH USE ONLY' and 'NOT INTENDED FOR HUMAN USE' statements.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA said the products are not generally recognized as safe and effective for the claimed uses and are therefore 'new drugs.'
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved applications are in effect for the products, so selling them across state lines violates the new-drug approval requirement.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks Xcel Research to notify it in writing within fifteen working days of steps taken to address the violations, prevent recurrence, and provide related documentation. If corrections cannot be completed in that time, the company must state why and give a completion date.
Who should pay attention
- companies selling peptides online
- suppliers of GLP-1-like peptides
- buyers of research-use-only peptide products
This is a summary. Read the original letter on fda.gov.